• Manufacturing agreement signed with Aurora, one of the world's largest medical cannabis producers
• Initial agreement covers supply of GMP-certified medicinal cannabis oils into the Australian market
• Agreement expanding to include GMP-manufactured cannabis vapes for supply into Australia, the UK and Germany

Bioxyne Ltd, an Australian-headquartered international consumer health and pharmaceutical company, has announced that its wholly owned subsidiary Breathe Life Sciences (BLS) has entered into a manufacturing agreement with Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company. Under the agreement, BLS will manufacture pharmaceutical-grade medicinal cannabis products for supply into key international markets. The initial agreement covers the supply of GMP-certified medicinal cannabis oils into the Australian market, with initial deliveries already completed. The agreement is also expanding to include GMP-manufactured cannabis vapes for supply into Australia, the United Kingdom, and Germany. This partnership highlights Bioxyne's evolution from a leading Australian manufacturer to a globally recognised brand, capable of partnering with top-tier industry leaders like Aurora to meet the demands of highly-regulated, high-stakes environments. The agreement marks a significant validation of Bioxyne's GMP-certified expertise in producing precision-dosed cannabis formats, positioning the company as a trusted supplier on the world stage.

The companies have agreed to expand the scope of the manufacturing agreement and the onboarding process for the supply of additional product lines has commenced. This expansion includes a large quantity of vapes, which will be produced and distributed into the Australian, UK and German markets. Discussions are also progressing regarding the production of further products for supply into the for the Australian, UK and German markets, further expanding BLS's manufacturing capabilities and market presence.